NaPi2b targeting antibody-drug conjugates - ADC Therapeutics
Alternative Names: NaPi2b-PL2202Latest Information Update: 21 Jun 2024
At a glance
- Originator ADC Therapeutics
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and safety data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Mar 2024 NaPi2b targeting antibody-drug conjugate is available for licensing as of 06 Mar 2024. https://www.adctherapeutics.com/our-company/#partnering (ADC Therapeutics website, March 2024)
- 05 Mar 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) before March 2024